Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757795 | 0.92 | XDH (0.42) | XDHS1PR1IKBKETBK1 | |
| SCHEMBL15539260 | 0.91 | XDH (0.46) | XDHSLC22A12S1PR1IKBKETBK1 | |
| SCHEMBL16757956 | 0.91 | RARB (0.44) | RARARARBSSTR5KCNH2CHRM4 | |
| SCHEMBL21043497 | 0.91 | XDH (0.40) | XDHIKBKETBK1CHRM4CHRM2 | |
| SCHEMBL20053622 | 0.90 | XDH (0.41) | XDHKCNH2IKBKETBK1 | |
| SCHEMBL15538323 | 0.89 | XDH (0.52) | XDHSSTR5KCNH2S1PR1IKBKE | |
| SCHEMBL15559048 | 0.87 | MTOR (0.41) | XDHKCNH2 | |
| SCHEMBL15559047 | 0.87 | MTOR (0.41) | XDHKCNH2 | |
| SCHEMBL16777192 | 0.86 | PIK3CA (0.42) | XDHKCNH2IKBKETBK1 | |
| SCHEMBL16777175 | 0.86 | PIK3CA (0.42) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| EP-3074384-B1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-05-22 | — | — | EP | disclosed |
| US-9944600-B2 | Piperidine derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | disclosed |
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-18 | — | — | US | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166480-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GPR84 | XDH 4342/4885SLC22A12 829/4885RARA 825/4885 |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GLP1R | XDH 3886/4885SLC22A12 694/4885RARA 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.